急性肺損傷の世界市場レポート 2025年

急性肺損傷の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR4.4％で30億9,000万米ドルに成長します。予測期間中の成長は、生物製剤や遺伝子治療の進歩、政府からの資金提供や助成金、精密医療、再生医療、幹細胞治療の開発、世界の医療政策改革などによって牽引される可能性があります。この時期の主な動向としては、生物学的製剤の開発、ウェアラブルデバイスや遠隔モニタリングデバイス、吸入ベースの療法、CRISPRや遺伝子編集技術、リアルタイム分析のためのバイオセンサーの使用などが挙げられます。

呼吸器疾患の有病率の増加は、急性肺損傷市場の成長を促進すると予想されます。呼吸器疾患は、肺や呼吸器系の他の部分に影響を及ぼし、呼吸困難や肺機能障害につながるさまざまな状態を包含します。これらの疾患の罹患率の上昇は、大気汚染の増加、喫煙、座りがちなライフスタイル、高齢化、ウイルス感染の影響などの要因に起因しています。肺炎などの病態は、重度の炎症を引き起こし、肺胞を損傷することでガス交換を損ない、呼吸困難をもたらすため、急性肺損傷につながる可能性があります。例えば、2023年9月、オーストラリア統計局は、オーストラリアにおけるインフルエンザおよび肺炎による死亡率の上昇を報告し、2021年の人口10万人当たり31.9人から2022年には42.6人へと、33.54％の大幅な増加を反映しました。このように、呼吸器疾患の有病率の増加は、急性肺損傷市場の拡大に拍車をかけています。

急性肺損傷市場の企業は、市場での地位を維持するため、ペプチド治療などの新規治療法の開発に注力しています。ペプチド治療とは、短い鎖状のアミノ酸（ペプチド）を治療薬として使用するものです。例えば、2022年11月、インドのヘルスケア企業であるZuventus Healthcare Ltd.は、急性呼吸窮迫症候群（ARDS）の治療薬としてAviptadilを発売しました。この治療薬には、プロスタサイクリンの50倍の効果を持つ強力な血管拡張作用、肺胞II型細胞に結合して界面活性剤の産生を高める肺保護メカニズム、IL-6やTNF-αなどの炎症性サイトカインを抑制する抗炎症作用、肺の免疫反応を調節する免疫調節作用など、いくつかの独自の利点があります。アビプタジルは、重症のウイルス性ARDS患者の転帰を改善する臨床効果も示しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界急性肺損傷PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の急性肺損傷市場：成長率分析
• 世界の急性肺損傷市場の実績：規模と成長, 2019-2024
• 世界の急性肺損傷市場の予測：規模と成長, 2024-2029, 2034F
• 世界急性肺損傷総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の急性肺損傷市場傷害の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 直接的な傷害
• 間接的な傷害
• 世界の急性肺損傷市場：セラピー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 機械的人工呼吸器
• 薬物療法
• 体液管理
• その他の治療法
• 世界の急性肺損傷市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他のエンドユーザー
• 世界の急性肺損傷市場、直接傷害の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• トラウマ誘発性急性肺損傷
• 誤嚥性肺炎
• 肺炎関連急性肺損傷
• 吸入傷害
• 世界の急性肺損傷市場間接傷害の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 敗血症関連急性肺損傷
• ショック誘発型急性肺損傷
• 急性肺損傷輸血別
• 膵炎に関連する急性肺損傷

第7章 地域別・国別分析

• 世界の急性肺損傷市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の急性肺損傷市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 急性肺損傷市場：競合情勢
• 急性肺損傷市場：企業プロファイル
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
  • Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Ono Pharmaceutical Co Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Aster DM Healthcare
• Octapharma AG
• Cartesian Therapeutics Inc.
• Vapotherm Inc.
• Stemedica Cell Technologies Inc.
• Implicit Bioscience Ltd.
• Apeiron Biologics AG
• Faron Pharmaceuticals Ltd.
• Histocell Sociedad Limitada
• Vasomune Therapeutics Inc
• Windtree Therapeutics Inc.
• Qx Therapeutics Inc.
• Asklepion Pharmaceuticals LLC
• ReAlta Life Sciences Inc.
• MediciNova Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 急性肺損傷市場2029：新たな機会を提供する国
• 急性肺損傷市場2029：新たな機会を提供するセグメント
• 急性肺損傷市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Acute lung injury (ALI) is a serious condition marked by widespread inflammation and damage to the lungs, resulting in impaired oxygen exchange. It can be caused by direct factors such as pneumonia or trauma, or indirect causes such as sepsis or pancreatitis. Symptoms of ALI include shortness of breath, low oxygen levels, and respiratory distress.

The primary types of acute lung injury are direct injury and indirect injury. Direct injury occurs when damage happens as a direct result of an event, action, or incident. Treatment options for ALI include mechanical ventilation, pharmacotherapy, fluid management, and others. These therapies are utilized by a range of end users, such as hospitals, clinics, and other healthcare facilities.

The acute lung injury market research report is one of a series of new reports from The Business Research Company that provides acute lung injury market statistics, including acute lung injury industry global market size, regional shares, competitors with acute lung injury market share, detailed acute lung injury market segments, market trends and opportunities, and any further data you may need to thrive in the acute lung injury industry. This acute lung injury market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute lung injury market size has grown steadily in recent years. It will grow from $2.48 billion in 2024 to $2.60 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth during the historic period can be attributed to awareness campaigns, an increase in ICU admissions, factors such as smoking and air pollution, hospital-acquired infections, and efforts to reduce mortality rates.

The acute lung injury market size is expected to see steady growth in the next few years. It will grow to $3.09 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth during the forecast period can be driven by advancements in biologics and gene therapies, government funding and grants, the development of precision medicine, regenerative medicine, stem cell therapies, and global health policy reforms. Key trends in this period include the development of biologic drugs, wearable and remote monitoring devices, inhalation-based therapies, CRISPR and gene editing technologies, and the use of biosensors for real-time analysis.

The increasing prevalence of respiratory diseases is expected to drive the growth of the acute lung injury market. Respiratory diseases encompass a range of conditions that affect the lungs and other parts of the respiratory system, leading to breathing difficulties and impaired lung function. The rising incidence of these diseases can be attributed to factors such as increased air pollution, smoking, sedentary lifestyles, aging populations, and the impact of viral infections. Conditions such as pneumonia can lead to acute lung injury by causing severe inflammation and damaging the alveoli, which impairs gas exchange and results in respiratory distress. For example, in September 2023, the Australian Bureau of Statistics reported a rise in the death rate from influenza and pneumonia in Australia, increasing from 31.9 per 100,000 people in 2021 to 42.6 per 100,000 people in 2022, reflecting a substantial 33.54% increase. As such, the growing prevalence of respiratory diseases is fueling the expansion of the acute lung injury market.

Companies in the acute lung injury market are concentrating on developing novel treatments, such as peptide therapies, to maintain their market position. Peptide treatments involve using short chains of amino acids (peptides) as therapeutic agents for medical conditions. For instance, in November 2022, Zuventus Healthcare Ltd., an India-based healthcare company, launched Aviptadil for treating acute respiratory distress syndrome (ARDS). This treatment offers several unique benefits, including potent vasodilatory effects that are 50 times more effective than prostacyclin, a lung protection mechanism that enhances surfactant production by binding to alveolar type II cells, anti-inflammatory properties that suppress pro-inflammatory cytokines such as IL-6 and TNF-alpha, and immunomodulatory action to regulate immune responses in the lungs. Aviptadil has also shown clinical effectiveness in improving outcomes for patients with severe viral-related ARDS.

In September 2024, Ligand Pharmaceuticals Inc., a US-based biopharmaceutical company, acquired Apeiron Biologics AG for $100 million. This acquisition strengthens Ligand's portfolio by integrating innovative therapies, particularly in immunotherapy and cancer treatment. It also expands Ligand's research and development capabilities, opening up new revenue opportunities and reinforcing its position in the biotech industry. Apeiron Biologics AG, an Austria-based biotechnology company, is actively involved in developing treatments for acute lung injury (ALI).

Major players in the acute lung injury market are Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Medtronic plc, Baxter International Inc., Ono Pharmaceutical Co Ltd., Aster DM Healthcare, Octapharma AG, Cartesian Therapeutics Inc., Vapotherm Inc., Stemedica Cell Technologies Inc., Implicit Bioscience Ltd., Apeiron Biologics AG, Faron Pharmaceuticals Ltd., Histocell Sociedad Limitada, Vasomune Therapeutics Inc, Windtree Therapeutics Inc., Qx Therapeutics Inc., Asklepion Pharmaceuticals LLC, ReAlta Life Sciences Inc., and MediciNova Inc.

North America was the largest region in the acute lung injury market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute lung injury report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute lung injury market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute lung injury market consists of revenues earned by entities by providing services such as intensive care unit (ICU) care, mechanical ventilation, oxygen therapy, extracorporeal membrane oxygenation, and pulmonary rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute lung injury market also includes sales of mechanical ventilators, oxygen therapy products, inhaled medications, sedation and analgesics, and diuretics. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Lung Injury Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute lung injury market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute lung injury ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute lung injury market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Injury Type: Direct Injury; Indirect Injury
• 2) By Therapy: Mechanical Ventilation; Pharmacotherapy; Fluid Management; Other Therapies
• 3) By End User: Hospitals; Clinics; Other End Users
• Subsegments:
• 1) By Direct Injury: Trauma-Induced Acute Lung Injury; Aspiration Pneumonitis; Pneumonia-Related Acute Lung Injury; Inhalation Injury
• 2) By Indirect Injury: Sepsis-Related Acute Lung Injury; Shock-Induced Acute Lung Injury; Acute Lung Injury Due To Blood Transfusion; Acute Lung Injury Associated With Pancreatitis
• Companies Mentioned: Thermo Fisher Scientific Inc.; GlaxoSmithKline plc; Medtronic plc; Baxter International Inc.; Ono Pharmaceutical Co Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute Lung Injury Market Characteristics

3. Acute Lung Injury Market Trends And Strategies

4. Acute Lung Injury Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Acute Lung Injury Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acute Lung Injury PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acute Lung Injury Market Growth Rate Analysis
• 5.4. Global Acute Lung Injury Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acute Lung Injury Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acute Lung Injury Total Addressable Market (TAM)

6. Acute Lung Injury Market Segmentation

• 6.1. Global Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Injury
• Indirect Injury
• 6.2. Global Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mechanical Ventilation
• Pharmacotherapy
• Fluid Management
• Other Therapies
• 6.3. Global Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End Users
• 6.4. Global Acute Lung Injury Market, Sub-Segmentation Of Direct Injury, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Trauma-Induced Acute Lung Injury
• Aspiration Pneumonitis
• Pneumonia-Related Acute Lung Injury
• Inhalation Injury
• 6.5. Global Acute Lung Injury Market, Sub-Segmentation Of Indirect Injury, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sepsis-Related Acute Lung Injury
• Shock-Induced Acute Lung Injury
• Acute Lung Injury Due To Blood Transfusion
• Acute Lung Injury Associated With Pancreatitis

7. Acute Lung Injury Market Regional And Country Analysis

• 7.1. Global Acute Lung Injury Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acute Lung Injury Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Lung Injury Market

• 8.1. Asia-Pacific Acute Lung Injury Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Lung Injury Market

• 9.1. China Acute Lung Injury Market Overview
• 9.2. China Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Lung Injury Market

• 10.1. India Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Lung Injury Market

• 11.1. Japan Acute Lung Injury Market Overview
• 11.2. Japan Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Lung Injury Market

• 12.1. Australia Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Lung Injury Market

• 13.1. Indonesia Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Lung Injury Market

• 14.1. South Korea Acute Lung Injury Market Overview
• 14.2. South Korea Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Lung Injury Market

• 15.1. Western Europe Acute Lung Injury Market Overview
• 15.2. Western Europe Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Lung Injury Market

• 16.1. UK Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Lung Injury Market

• 17.1. Germany Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Lung Injury Market

• 18.1. France Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Lung Injury Market

• 19.1. Italy Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Lung Injury Market

• 20.1. Spain Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Lung Injury Market

• 21.1. Eastern Europe Acute Lung Injury Market Overview
• 21.2. Eastern Europe Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Lung Injury Market

• 22.1. Russia Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Lung Injury Market

• 23.1. North America Acute Lung Injury Market Overview
• 23.2. North America Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Lung Injury Market

• 24.1. USA Acute Lung Injury Market Overview
• 24.2. USA Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Lung Injury Market

• 25.1. Canada Acute Lung Injury Market Overview
• 25.2. Canada Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Lung Injury Market

• 26.1. South America Acute Lung Injury Market Overview
• 26.2. South America Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Lung Injury Market

• 27.1. Brazil Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Lung Injury Market

• 28.1. Middle East Acute Lung Injury Market Overview
• 28.2. Middle East Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Lung Injury Market

• 29.1. Africa Acute Lung Injury Market Overview
• 29.2. Africa Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Lung Injury Market Competitive Landscape And Company Profiles

• 30.1. Acute Lung Injury Market Competitive Landscape
• 30.2. Acute Lung Injury Market Company Profiles
  • 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Ono Pharmaceutical Co Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Acute Lung Injury Market Other Major And Innovative Companies

• 31.1. Aster DM Healthcare
• 31.2. Octapharma AG
• 31.3. Cartesian Therapeutics Inc.
• 31.4. Vapotherm Inc.
• 31.5. Stemedica Cell Technologies Inc.
• 31.6. Implicit Bioscience Ltd.
• 31.7. Apeiron Biologics AG
• 31.8. Faron Pharmaceuticals Ltd.
• 31.9. Histocell Sociedad Limitada
• 31.10. Vasomune Therapeutics Inc
• 31.11. Windtree Therapeutics Inc.
• 31.12. Qx Therapeutics Inc.
• 31.13. Asklepion Pharmaceuticals LLC
• 31.14. ReAlta Life Sciences Inc.
• 31.15. MediciNova Inc.

32. Global Acute Lung Injury Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Lung Injury Market

34. Recent Developments In The Acute Lung Injury Market

35. Acute Lung Injury Market High Potential Countries, Segments and Strategies

• 35.1 Acute Lung Injury Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acute Lung Injury Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acute Lung Injury Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer